A new advertising campaign spearheaded by Democratic strategists aims to excoriate congressional Republicans and the Trump administration for opposing Speaker Nancy Pelosi Nancy PelosiMcConnell focuses on confirming judicial nominees with COVID-19 talks stalled Overnight Defense: Top admiral says 'no condition' where US should conduct nuclear test 'at this time' | Intelligence chief says Congress will get some in-person election security briefings Pelosi must go — the House is in dire need of new leadership MORE’s (D-Calif.) drug pricing legislation.

The Patients Over Pharma campaign is run by Accountable.US, an umbrella organization of progressive watchdog groups that attacks the Trump administration’s apparent conflicts of interest and ties to industry groups.

Lowering drug prices polls consistently as one of the top issues for voters, and the ad campaign is an example of how Democrats and progressive groups plan to spotlight Pelosi’s sweeping bill as the central piece to their health messaging in 2020.

ADVERTISEMENT

The group declined to say how large the budget was for the project, which will include running ads throughout the election season.

The new campaign “will focus on exposing the deep ties between the Trump administration and the pharmaceutical industry, the revolving door between Big Pharma and the federal government, and how this corruption is hurting patients and preventing any meaningful progress toward reducing the cost of prescription drugs,” Kyle Herrig, president of Accountable.US, said in a statement.

“Exposing Big Pharma influence and corruption and calling on policymakers to keep their promises is going to be absolutely critical in the months ahead,” Herrig added.

A spokesman noted that the ads will be focused on the issue of drug pricing only and will not advocate for or against any particular candidates.

The campaign launched on the heels of the House passage of H.R. 3, Pelosi’s signature drug pricing legislation which would allow the government to negotiate lower prices for prescription drugs.

ADVERTISEMENT

The bill has already been declared “dead on arrival” in the Republican-controlled Senate, but Democrats argue that price negotiation is the only meaningful way to bring down prescription drug prices and reform the pharmaceutical industry.

Senate Majority Leader Mitch McConnell Addison (Mitch) Mitchell McConnellMcConnell focuses on confirming judicial nominees with COVID-19 talks stalled McConnell accuses Democrats of sowing division by 'downplaying progress' on election security Warren, Schumer introduce plan for next president to cancel ,000 in student debt MORE (R-Ky.) is also reluctant to hold a vote on a separate bipartisan bill, sponsored by Senate Finance Committee Chairman Chuck Grassley Charles (Chuck) Ernest GrassleySenate Republicans signal openness to working with Biden Senators offer disaster tax relief bill Trump spikes political football with return of Big Ten season MORE (R-Iowa) and ranking member Ron Wyden Ronald (Ron) Lee WydenGOP senator blocks Schumer resolution aimed at Biden probe as tensions run high Republican Senators raise concerns over Oracle-TikTok deal Hillicon Valley: TikTok, Oracle seek Trump's approval as clock winds down | Hackers arrested for allegedly defacing U.S. websites after death of Iranian general | 400K people register to vote on Snapchat MORE (D-Ore.), that would limit the price increases drug companies typically make every year.

During the 2016 campaign, Trump famously broke with his party and said he supported letting the government negotiate drug prices. But the White House distanced itself from Pelosi’s bill and eventually came out against the legislation.

Democrats think highlighting Trump’s lack of follow-through on negotiating drug prices for Medicare will be a strong line of attack in next year's elections.